脑出血后房颤抗凝的净临床获益分析
基于GERFHS III人群回顾性研究,对95例房颤合并脑出血患者用马尔可夫模型评估抗凝净临床获益。结果示全体抗凝净损失0.92 QALY,71%患者出血风险高于缺血风险,仅约12%获临床显著获益。
要点
- 脑出血后房颤患者普遍抗凝可能净损失QALY。
- 71%患者大出血风险高于缺血性卒中风险。
- 抗凝决策需个体化,不宜对所有患者统一抗凝。
核心结论
- 脑出血后对所有房颤患者普遍抗凝与QALY净损失相关。
- 抗凝前需考虑额外因素以个体化决策。
研究设计与样本
- GERFHS III研究为基于人群的回顾性研究,纳入2008年7月至2012年12月大辛辛那提/北肯塔基地区无结构或创伤原因的自发性脑出血患者。
- 共1186例自发性脑出血,其中95例合并房颤且符合生存标准。
- 计算CHA2DS2-VASc和HAS-B(L)ED评分,用马尔可夫状态转换模型估算抗凝相对于不治疗的质量调整生命年(QALY)净临床获益。
- 定义最小临床相关获益为0.1 QALY。
主要发现
- 1年内,95例中8例(8%)预期抗凝下发生大出血事件。
- 1年内,95例中5例(5%)预期不抗凝下发生缺血性卒中。
- 直接作用抗凝药使73%患者无临床显著获益或损失,约12%获>0.1 QALY获益,15%损失>0.1 QALY。
- 接受阿司匹林者多数无显著净临床获益或损失;全体抗凝总体损失0.92 QALY。
关键数值与推荐
- 最小临床相关获益阈值定义为0.1 QALY。
- 全体队列抗凝总体净损失0.92 QALY。
- 95例中8例(8%)预期抗凝下大出血,5例(5%)预期不抗凝下缺血性卒中。
- 直接作用抗凝药下73%无显著获益或损失,12%获>0.1 QALY,15%损失>0.1 QALY。
临床怎么用
- 脑出血后房颤患者不应默认普遍抗凝,需评估个体净临床获益。
- 可用CHA2DS2-VASc和HAS-B(L)ED评分辅助权衡缺血与出血风险。
- 对多数患者抗凝可能无显著净获益,决策前应综合考虑额外因素。
局限性
- 为回顾性研究,可能存在选择偏倚。
- HAS-BLED评分缺少labile INR成分,以HAS-B(L)ED替代。
- 样本量有限,95例房颤患者符合生存标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Patients with intracerebral hemorrhage (ICH) and atrial fibrillation (AF) are at risk for ischemic events. While risk calculators (CHA2DS2-VASc and HAS-BLED) have been validated to assess risk for ischemic stroke and major bleeding in AF patients, decisions about anticoagulation must consider the net clinical benefit of anticoagulation. Furthermore, stroke and bleeding risk are highly correlated, making decisions more difficult. Methods- We examined patients in the GERFHS III study (Genetic and Environmental Risk Factors for Hemorrhagic Stroke)-a population-based retrospective study of spontaneous ICH patients without a structural or traumatic cause in the Greater Cincinnati/Northern Kentucky region between July 2008 and December 2012. CHA2DS2-VASc and HAS-B(L)ED (minus L because labile international normalized ratio was unavailable) scores were calculated for ICH patients with AF. Using a Markov state transition model, we estimated net clinical benefit of anticoagulation relative to no treatment in quality-adjusted life years (QALYs). We defined minimal clinically relevant benefit as 0.1 QALYs. Results- Among 1186 cases of spontaneous ICH, 95 cases had AF and met our survival criteria. Within 1 year, 8 of 95 (8%) would be expected to have a major bleeding event on anticoagulation, and 5 of 95 (5%) of patients would be expected to have an ischemic stroke off anticoagulation. Sixty-eight of 95 (71%) patients would have higher risk for major bleeding than for ischemic stroke. Anticoagulation with directly acting anticoagulants would result in no clinically significant gain or loss in 73%. Roughly 12% would gain >0.1 QALYs, and 15% would lose >0.1 QALYs. Among patients receiving aspirin, most have no significant net clinical benefit or loss. Overall, anticoagulation of the entire cohort would result in an aggregate loss of 0.92 QALYs. Conclusions- Our analysis suggests that universal anticoagulation after ICH would be associated with a net loss of QALY. Additional factors should be considered before anticoagulating patients with AF after ICH. Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT00930280.
引用
- Stanton RJ, Eckman MH, Woo D, et al. Ischemic Stroke and Bleeding: Clinical Benefit of Anticoagulation in Atrial Fibrillation After Intracerebral Hemorrhage. Stroke. 2020. PMID: 32000590. doi:10.1161/STROKEAHA.119.027370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。